Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pfizer, Elan Performances Suggest Investor Comfort With Drug Safety Issues

Executive Summary

Increased confidence in Elan/Biogen's ability to return the multiple sclerosis therapy Tysabri to the market by the fall could be a signal that pharma and biotech companies have turned the corner on drug safety issues

You may also be interested in...

Bristol $300 Mil. DoJ Settlement Includes Separation OF CEO/Chairman Roles

Bristol-Myers Squibb board member James Robinson will take on additional corporate governance oversight responsibilities, including meeting with execs prior to analyst calls, as the newly-appointed chairman

Bristol’s DTC Moratorium Will Affect Muraglitazar, Abatacept Launches

Muraglitazar and abatacept are likely to be the first Bristol-Myers Squibb products significantly affected by the company's recent moratorium on direct-to-consumer advertising during a drug's first 12 months on the market

Merck Taps Clark As CEO In Nod To Medco Heritage; Gilmartin To Retire

Merck's appointment of Richard Clark to succeed retiring CEO Ray Gilmartin continues the Medco legacy at Merck's senior management level

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts